Anixa Biosciences congratulates Director Dr Arnold Baskies on his appointment to the WHO Global Breast Cancer Initiative


SAN JOSE, California, 23 Aug 2021 / PRNewswire / – Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, today announced that its director, Dr. Arnold baskies was appointed to the Global Breast Cancer Initiative of the World Health Organization (WHO).

Anixa Biosciences, Inc. (PRNewsfoto / Anixa Biosciences, Inc.)

Dr Baskies is an ardent cancer fighter. At the individual patient level, he has battled cancer as a surgical oncologist for more than three decades. He also had an instrumental affiliation with the American Cancer Society (ACS), the largest cancer-fighting nonprofit. At ACS, he has held many positions, including the company’s board of directors, as well as chairman of the board. In his new role at WHO, Dr Baskies will have the opportunity to make an impact on breast cancer on the global stage.

Dr Baskies is a fellowship-trained surgical oncologist with a particular interest in breast cancer, thyroid cancer and melanoma. He obtained his Bachelor of Arts, summa cum laude, and was a member of Phi Beta Kappa at Boston university. He graduated from the Boston University School of Medicine, and completed his surgical residency at Boston Medical Center. Dr Baskies also completed a fellowship in surgical oncology at the National Cancer Institute, where he did some of the earliest research in T cells and the field that is now known as immunotherapy.

Dr. Amit Kumar, President and CEO of Anixa Biosciences said, “We are delighted that Arnie is working with WHO on the Global Breast Cancer Initiative. We are also touched by his continued contribution to our business as a member of our Board of Directors. Breast cancer is now the most frequently diagnosed cancer in the world. Our breast cancer vaccine, which we are developing in partnership with the Cleveland Clinic and the US Department of Defense, is expected to begin clinical trials soon. It would be wonderful if we could provide the women of our world with a powerful tool that could prevent the onset of breast cancer. “

Dr Baskies said: “I am honored to work with WHO in this capacity and look forward to helping prevent breast cancer and improve outcomes and the lives of those diagnosed. Medical and scientific advances in breast cancer are going to be revolutionary in the years to come, and we hope that Anixa and its partners will make important contributions. “

More information on the WHO Global Breast Cancer Initiative is available at: initiative-highlights-renewed-commitment- to-improve-survival.

About Anixa Biosciences, Inc.
Anixa is a publicly traded biotechnology company that develops a number of cancer and infectious disease programs. Anixa’s therapeutic portfolio includes a cancer immunotherapy program that uses a new type of CAR-T, known as chimeric endocrine receptor (CER-T) T cell technology, and a Covid-19 therapeutic program. focused on inhibiting certain functions of viral proteins. The company’s vaccine portfolio includes a vaccine to prevent breast cancer, and in particular triple negative breast cancer (TNBC), the deadliest form of the disease, and a vaccine to prevent ovarian cancer . These vaccine technologies focus on immunization against specific proteins that have been shown to be expressed in certain forms of cancer. Anixa continuously examines emerging technologies in complementary areas for further development and commercialization. Additional information is available at

Forward-looking statements: Statements that are not historical fact may be considered as forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are not statements of historical fact, but rather reflect Anixa’s current expectations regarding future events and results. We generally use the words “believes”, “expects”, “intention”, “plans”, “anticipates”, “likely”, “will” and similar expressions to identify forward-looking statements. These forward-looking statements, including those regarding our expectations, involve risks, uncertainties and other factors, some of which are beyond our control, that may cause our actual results, performance or achievements, or the results of the industry, are materially different from any future results, performances or achievements expressed or implied by such forward-looking statements. These risks, uncertainties and factors include, without limitation, the factors set out in “Section 1A – Risk Factors” and other sections of our most recent annual report on Form 10-K as well as in our reports. quarterly on Form 10 -Q and current reports on Form 8-K. We assume no obligation to publicly update or revise forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. You are cautioned not to place undue reliance on these forward-looking statements when evaluating the information presented in this press release.

Mike Catelani
[email protected]



View original content to download multimedia: -breast -initiative-cancer-301360318.html

SOURCE Anixa Biosciences, Inc.

Source link

Leave A Reply

Your email address will not be published.